JPMorgan Chase & Co. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated June 30, 2023, discloses the results of JPMorgan Chase & Co.'s company-run 2023 Dodd-Frank Act Stress Test (DFAST). The filing covers both JPMorgan Chase and JPMorgan Chase Bank, National Association.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a disclosure notice for stress test results rather than a financial statement containing operational metrics. The actual stress test results are contained in Exhibit 99, which is referenced but not detailed in the provided text.
Material Changes
No material changes to financial performance or position are reported in this specific filing text. The report focuses on the submission of hypothetical stress test scenarios rather than actual period-over-period financial changes.
Guidance, Outlook, and Risks
- Stress Test Scenario: The results reflect the "Supervisory Severely Adverse" scenario and market shock assumptions provided by the Federal Reserve Board on February 9, 2023.
- Regulatory Status: The furnishing of these results is not an indication of the Federal Reserve Board's judgment regarding the firm's proposed capital actions.
- Forward-Looking Statements: The report contains forward-looking statements subject to significant risks and uncertainties. Actual results may differ materially from expectations.
- Liability Disclaimer: Information in Exhibit 99 is not deemed "filed" under Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99 (2023 Annual Stress Test Disclosure) for specific capital ratios and stress test outcomes.
- Consult the Federal Reserve Board website for the "Supervisory Severely Adverse" scenario assumptions used in the test.
- Refer to the most recent Form 10-K and Form 10-Q for actual financial performance and risk factors.
- Verify that the stress test results do not constitute a regulatory approval of proposed capital actions.